Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Organon Pharma Indonesia Tbk. (SCPI) vs Satyamitra Kemas Lestari Tbk. (SMKL) Price & Performance

Organon Pharma Indonesia Tbk.Trade
Satyamitra Kemas Lestari Tbk.Trade

Price performance (Past 24H)

Key statistics

Organon Pharma Indonesia Tbk. vs Satyamitra Kemas Lestari Tbk. — how do they compare? Organon Pharma Indonesia Tbk. trades at Rp29,000 (market cap 104.4B), while Satyamitra Kemas Lestari Tbk. trades at Rp153 (market cap 536.64B, 92.3K 24h volume). The key difference: Satyamitra Kemas Lestari Tbk. is far larger — about 5.1× Organon Pharma Indonesia Tbk.'s market cap. Which is the better fit depends on your goals.

SCPISMKL
Market Cap
104.4B536.64B
Volume
92.3K
Lot
923
Turnover
14.17M
Average Price
153.5
Value
14.17M
Indicative Equilibrium Price
153
Indicative Equilibrium Volume
318

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

SCPI
View details
SMKL
View details

About Organon Pharma Indonesia Tbk.

PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.

Read more on SCPI

About Satyamitra Kemas Lestari Tbk.

PT Satyamitra Kemas Lestari Tbk (The Company) was established based on Deed of Establishment No. 12 dated July 26, 2001 which was made in the presence of Juniaty Tedjaputra, S.H., a notary in Tangerang.

Read more on SMKL